• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

The Continuing Impact of NIPS on Invasive Diagnostic Testing

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Since screening for fetal chromosomal anomalies became clinically available in 2012, the use of amniocentesis and CVS continue to decline
  • Ibraheem et al. (Amer J Perinatol, 2017) surveys the magnitude of decline and changes in indications for invasive prenatal testing over the past 6 years in a tertiary care setting

METHODS:

  • Retrospective Cohort Study (2010 – 2015)
  • The total number of patients choosing either option was determined per year
  • Indications
    • Screen positive aneuploidy screening, advanced maternal age, abnormal ultrasound finding, personal or family history of genetic anomaly or other
  • Advanced maternal age patients were offered (1) NIPS or (2) invasive testing or (3) routine NT screening
  • Statistical analysis included logistic regression and chi-square test

RESULTS:

  • The number of patients seeking genetic counseling did not decrease throughout the study period, but the number of invasive procedures declined steadily from 429 amnios and 154 CVs in 2010 to 72 amnios and 60 CVS in 2015 (p < 0.001)
  • 61% of the study cohort had genetic counseling for advanced maternal age
  • The percentage of patients opting for invasive procedures with AMA as the sole indication declined significantly from 38% in 2010 to 2% in 2015 (p < 0.0001)
  • The rate of advanced maternal age women opting for NIPS increased markedly from 28% in 2012 to 91% in 2015 (p < 0.0001)
  • The proportion of procedures performed due to advanced maternal age or aneuploidy screening declined significantly over time (p<0.001) at an average rate of 45% (95% CI: 36–55%)
  • Aneuploidy screening (positive) as an indication
    • Invasive procedures declined from 139 to 21 (2010 – 2015)
  • Advanced maternal age as an indication
    • Invasive procedures declined from 277 to 25 (2010 – 2015)

CONCLUSION:

  • NIPS is not an alternative to diagnostic testing as it is only a screening test
  • Even in ‘high’ risk populations such as advanced maternal age, patients are opting for screening with NIPS
  • The authors raise concern regarding training for invasive procedures among the next generation of specialists
  • Considering this trend, it is critical that women understand the difference between screening (NIPS) and diagnostics (amnio and CVS) for the purposes of informed decision making

Learn More – Primary Sources:

Changing Face of Invasive Diagnostic Testing in the Era of Cell-Free DNA

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Should Amniocentesis or Chorionic Villus Sampling Be Offered to All Pregnant Women?
Fetal loss after amnio or CVS – what is the risk ?
Does Amniocentesis or CVS Increase the risk of HIV Vertical Transmission?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site